메뉴 건너뛰기




Volumn 83, Issue 976, 2007, Pages 73-78

Medical treatment of benign prostatic hyperplasia

Author keywords

[No Author keywords available]

Indexed keywords

ALFUZOSIN; DOXAZOSIN; FINASTERIDE; PYGEUM AFRICANUM EXTRACT; SABAL EXTRACT; TAMSULOSIN; TERAZOSIN;

EID: 33847414526     PISSN: 00325473     EISSN: None     Source Type: Journal    
DOI: 10.1136/pgmj.2006.050724     Document Type: Review
Times cited : (5)

References (114)
  • 1
    • 0032032069 scopus 로고    scopus 로고
    • Heath-related quality of life associated with lower urinary tract symptoms in four countries
    • Girman CJ, Jacobsen SJ, Tsukamoto T, et al. Heath-related quality of life associated with lower urinary tract symptoms in four countries. Urology 1998;51:428-36.
    • (1998) Urology , vol.51 , pp. 428-436
    • Girman, C.J.1    Jacobsen, S.J.2    Tsukamoto, T.3
  • 2
    • 0034006010 scopus 로고    scopus 로고
    • The development and validation of a quality of life measure to assess partner morbidity in benign prostatic enlargement
    • Sells H, Donovan J, Ewings P, et al. The development and validation of a quality of life measure to assess partner morbidity in benign prostatic enlargement. BJU Int 2000;85:440-5.
    • (2000) BJU Int , vol.85 , pp. 440-445
    • Sells, H.1    Donovan, J.2    Ewings, P.3
  • 3
    • 0032705466 scopus 로고    scopus 로고
    • Management of symptomatic BPH in the US: Who is treated and how?
    • Bruskewitz R. Management of symptomatic BPH in the US: who is treated and how? Eur Urol 1999;36(Suppl 3):7-13.
    • (1999) Eur Urol , vol.36 , Issue.SUPPL. 3 , pp. 7-13
    • Bruskewitz, R.1
  • 4
    • 0024584090 scopus 로고
    • Transurethral prostalectomy: Practice aspects of the dominant operation in American urology
    • Holtgrewe H, Mebust W, Dowd J, et al. Transurethral prostalectomy: practice aspects of the dominant operation in American urology. J Urol 1989;141:248-53.
    • (1989) J Urol , vol.141 , pp. 248-253
    • Holtgrewe, H.1    Mebust, W.2    Dowd, J.3
  • 5
    • 0033152755 scopus 로고    scopus 로고
    • Trends in prostatectomy for benign prostatic hyperplasia among black and white men in the United States: 1980-94
    • Xia Z, Roberts RO, Schottenfeld D, et al. Trends in prostatectomy for benign prostatic hyperplasia among black and white men in the United States: 1980-94. Urology 1999;53:1154-9.
    • (1999) Urology , vol.53 , pp. 1154-1159
    • Xia, Z.1    Roberts, R.O.2    Schottenfeld, D.3
  • 6
    • 0028673062 scopus 로고
    • Transurethral resection of the prostate among Medicare beneficiaries in the United States: Time trends and outcomes. Prostate patient outcome research team (PORT)
    • Lu Yao G, Barry M, Chang C, et al. Transurethral resection of the prostate among Medicare beneficiaries in the United States: time trends and outcomes. Prostate patient outcome research team (PORT). Urology 1994;44:692-8.
    • (1994) Urology , vol.44 , pp. 692-698
    • Lu Yao, G.1    Barry, M.2    Chang, C.3
  • 7
    • 0032755424 scopus 로고    scopus 로고
    • Who should be treated and how? Evidence based medicine in symptomatic BPH
    • Speakman MJ. Who should be treated and how? Evidence based medicine in symptomatic BPH. Eur Urol 1999;36(Suppl 3):40-51.
    • (1999) Eur Urol , vol.36 , Issue.SUPPL. 3 , pp. 40-51
    • Speakman, M.J.1
  • 8
    • 33644824294 scopus 로고    scopus 로고
    • The natural history of benign prostatic hyperplasia
    • Fitzpatrick JM. The natural history of benign prostatic hyperplasia. BJU Int 2006;97(Suppl 2):3-6.
    • (2006) BJU Int , vol.97 , Issue.SUPPL. 2 , pp. 3-6
    • Fitzpatrick, J.M.1
  • 9
    • 0028965747 scopus 로고
    • Natural history of prostatism: Relationship among symptoms, prostate volume, and peak urinary flow rate
    • Girman CJ, Jacobsen SJ, Guess HA, et al. Natural history of prostatism: relationship among symptoms, prostate volume, and peak urinary flow rate. J Urol 1995;153:1510-15.
    • (1995) J Urol , vol.153 , pp. 1510-1515
    • Girman, C.J.1    Jacobsen, S.J.2    Guess, H.A.3
  • 10
    • 0028784340 scopus 로고
    • Natural history of benign prostatic hyperplasia: Appropriate case definition and estimate of its prevalence in the community
    • Bosch JLHR, Hop WCJ, Kirkels WJ, et al. Natural history of benign prostatic hyperplasia: appropriate case definition and estimate of its prevalence in the community. Urology 1995;46(Suppl 3A):34-40.
    • (1995) Urology , vol.46 , Issue.SUPPL. 3A , pp. 34-40
    • Bosch, J.L.H.R.1    Hop, W.C.J.2    Kirkels, W.J.3
  • 11
    • 0021149603 scopus 로고
    • The development of human benign prostatic hyperplasia by age
    • Berry SJ, Coffey DS, Walsh PC, et al. The development of human benign prostatic hyperplasia by age. J Urol 1984;132:474-9.
    • (1984) J Urol , vol.132 , pp. 474-479
    • Berry, S.J.1    Coffey, D.S.2    Walsh, P.C.3
  • 12
    • 0024832529 scopus 로고
    • Etiology and disease process of benign prostatic hyperplasia
    • Isaacs JT, Coffey DS. Etiology and disease process of benign prostatic hyperplasia. Prostate 1989;2(Suppl):33-50.
    • (1989) Prostate , vol.2 , Issue.SUPPL. , pp. 33-50
    • Isaacs, J.T.1    Coffey, D.S.2
  • 13
    • 0028673818 scopus 로고
    • Preliminary study of the frequency of benign prostatic hyperplasia and prostatic cancer in China
    • Gu FL, Xia TL, Kong XT. Preliminary study of the frequency of benign prostatic hyperplasia and prostatic cancer in China. Urology 1994;44:688-91.
    • (1994) Urology , vol.44 , pp. 688-691
    • Gu, F.L.1    Xia, T.L.2    Kong, X.T.3
  • 14
    • 0029998790 scopus 로고    scopus 로고
    • Japanese men have smaller prostates but comparable urinary flow rates relative to American men: Results of community based studies in 2 countries
    • Masumori N, Tsukamoto T, Kumamoto Y, et al. Japanese men have smaller prostates but comparable urinary flow rates relative to American men: results of community based studies in 2 countries. J Urol 1996;155:1324-27.
    • (1996) J Urol , vol.155 , pp. 1324-1327
    • Masumori, N.1    Tsukamoto, T.2    Kumamoto, Y.3
  • 15
    • 0030048698 scopus 로고    scopus 로고
    • International comparison of the community prevalence of the symptoms of prostatism in 4 countries
    • Sagnier PP, Girman CJ, Garraway M, et al. International comparison of the community prevalence of the symptoms of prostatism in 4 countries. Eur Urol 1996;29:15-20.
    • (1996) Eur Urol , vol.29 , pp. 15-20
    • Sagnier, P.P.1    Girman, C.J.2    Garraway, M.3
  • 16
    • 0030064611 scopus 로고    scopus 로고
    • Natural history of prostatism: Longitudinal changes in voiding symptoms in community-dwelling men
    • Jacobsen SJ, Girman CJ, Guess HA, et al. Natural history of prostatism: longitudinal changes in voiding symptoms in community-dwelling men. J Urol 1996;155:595-600.
    • (1996) J Urol , vol.155 , pp. 595-600
    • Jacobsen, S.J.1    Girman, C.J.2    Guess, H.A.3
  • 17
    • 0036301888 scopus 로고    scopus 로고
    • The placebo effect and randomized trials: Analysis of conventional medicine
    • Moyad MA. The placebo effect and randomized trials: analysis of conventional medicine. Urol Clin North Am 2002;29:ix-x.
    • (2002) Urol Clin North Am , vol.29
    • Moyad, M.A.1
  • 18
    • 0035652433 scopus 로고    scopus 로고
    • Natural history of benign prostatic hyperplasia
    • Jacobsen SJ, Girman CJ, Lieber MM. Natural history of benign prostatic hyperplasia. Urology 2001;58(Suppl 6A):5-16.
    • (2001) Urology , vol.58 , Issue.SUPPL. 6A , pp. 5-16
    • Jacobsen, S.J.1    Girman, C.J.2    Lieber, M.M.3
  • 19
    • 0013310546 scopus 로고    scopus 로고
    • Longitudinal prostate volume in a community based sample: 7-year follow-up in the Olmsted County Study of Urinary Symptoms and Health Status among men
    • Rhodes T, Girman C, Jacobsen D, et al. Longitudinal prostate volume in a community based sample: 7-year follow-up in the Olmsted County Study of Urinary Symptoms and Health Status among men. J Urol 2000;163:249.
    • (2000) J Urol , vol.163 , pp. 249
    • Rhodes, T.1    Girman, C.2    Jacobsen, D.3
  • 20
    • 0032882360 scopus 로고    scopus 로고
    • Longitudinal prostate growth rates during 5 years in randomly selected community men 40 to 79 years old
    • Rhodes T, Girman CJ, Jacobsen SJ, et al. Longitudinal prostate growth rates during 5 years in randomly selected community men 40 to 79 years old. J Urol 1999;161:1174-9.
    • (1999) J Urol , vol.161 , pp. 1174-1179
    • Rhodes, T.1    Girman, C.J.2    Jacobsen, S.J.3
  • 21
    • 0033992104 scopus 로고    scopus 로고
    • Longitudinal changes in peak urinary flow rates in a community based cohort
    • Roberts RO, Jacobsen SJ, Jacobsen DJ, et al. Longitudinal changes in peak urinary flow rates in a community based cohort. J Urol 2000;163:107-13.
    • (2000) J Urol , vol.163 , pp. 107-113
    • Roberts, R.O.1    Jacobsen, S.J.2    Jacobsen, D.J.3
  • 22
    • 0347882750 scopus 로고    scopus 로고
    • The long-term effect of doxazosin, finasteride and combination therapy on clinical progression of benign prostatic hyperplasia
    • McConnell JD, Roehrbom CG, Bautista OM, et al. The long-term effect of doxazosin, finasteride and combination therapy on clinical progression of benign prostatic hyperplasia. N Engl J Med 2003;349:2387-98.
    • (2003) N Engl J Med , vol.349 , pp. 2387-2398
    • McConnell, J.D.1    Roehrbom, C.G.2    Bautista, O.M.3
  • 23
    • 0030876630 scopus 로고    scopus 로고
    • Natural history of prostatism: Risk factors for acute urinary retention
    • Jacobsen SJ, Jacobsen DJ, Girman CJ, et al. Natural history of prostatism: risk factors for acute urinary retention. J Urol 1997;158:481-7.
    • (1997) J Urol , vol.158 , pp. 481-487
    • Jacobsen, S.J.1    Jacobsen, D.J.2    Girman, C.J.3
  • 24
    • 0032843335 scopus 로고    scopus 로고
    • Treatment for benign prostatic hyperplasia among community dwelling men: The Olmsted County study of urinary symptoms and health status
    • Jacobsen SJ, Jacobsen DJ, Girman CJ, et al. Treatment for benign prostatic hyperplasia among community dwelling men: the Olmsted County study of urinary symptoms and health status. J Urol 1999;162:1301- 6.
    • (1999) J Urol , vol.162 , pp. 1301-1306
    • Jacobsen, S.J.1    Jacobsen, D.J.2    Girman, C.J.3
  • 25
    • 0032828809 scopus 로고    scopus 로고
    • Incidence rates and risk factors for acute urinary retention: The Health Professionals Follow-up Study
    • Meigs JB, Barry MJ, Giovannucci E, et al. Incidence rates and risk factors for acute urinary retention: The Health Professionals Follow-up Study. J Urol 1999;162:376-82.
    • (1999) J Urol , vol.162 , pp. 376-382
    • Meigs, J.B.1    Barry, M.J.2    Giovannucci, E.3
  • 26
    • 0006075228 scopus 로고    scopus 로고
    • The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia
    • McConnell JD, Bruskewitz R, Walsh P, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med 1998;338:557-63.
    • (1998) N Engl J Med , vol.338 , pp. 557-563
    • McConnell, J.D.1    Bruskewitz, R.2    Walsh, P.3
  • 27
    • 28544443596 scopus 로고    scopus 로고
    • The natural history of lower urinary tract dysfunction in men: Minimum 10-year urodynamic follow-up of untreated bladder outlet obstruction
    • Thomas AW, Cannon A, Bartlett E, et al. The natural history of lower urinary tract dysfunction in men: minimum 10-year urodynamic follow-up of untreated bladder outlet obstruction. BJU Int 2005;96:1301-6.
    • (2005) BJU Int , vol.96 , pp. 1301-1306
    • Thomas, A.W.1    Cannon, A.2    Bartlett, E.3
  • 28
    • 33644823157 scopus 로고    scopus 로고
    • Definition of at-risk patients: Baseline variables
    • Roehrborn CG. Definition of at-risk patients: baseline variables. BJU Int 2006;97(Suppl 2):7-11.
    • (2006) BJU Int , vol.97 , Issue.SUPPL. 2 , pp. 7-11
    • Roehrborn, C.G.1
  • 29
    • 33644832528 scopus 로고    scopus 로고
    • Definition of at-risk patients: Dynamic variables
    • Emberton M. Definition of at-risk patients: dynamic variables. BJU Int 2006;97(Suppl 2):12-15.
    • (2006) BJU Int , vol.97 , Issue.SUPPL. 2 , pp. 12-15
    • Emberton, M.1
  • 30
    • 0032868620 scopus 로고    scopus 로고
    • Serum prostate specific antigen and prostate volume predict long-term changes in symptoms and flow rate: Results of a four-year, randomized trial comparing finasteride versus placebo. PLESS Study Group
    • Roehrborn CG, Boyle P, Bergner D, et al. Serum prostate specific antigen and prostate volume predict long-term changes in symptoms and flow rate: results of a four-year, randomized trial comparing finasteride versus placebo. PLESS Study Group. Urology 1999;54:662-9.
    • (1999) Urology , vol.54 , pp. 662-669
    • Roehrborn, C.G.1    Boyle, P.2    Bergner, D.3
  • 31
    • 23744468937 scopus 로고    scopus 로고
    • Symptom deterioration during treatment and history of AUR are the strongest predictors for AUR and BPH-related surgery in men with LUTS treated with alfuzosin 10 mg once daily
    • Emberton M, Elhilali M, Matzkin H, et al. Symptom deterioration during treatment and history of AUR are the strongest predictors for AUR and BPH-related surgery in men with LUTS treated with alfuzosin 10 mg once daily. Urology 2005;66:316-22.
    • (2005) Urology , vol.66 , pp. 316-322
    • Emberton, M.1    Elhilali, M.2    Matzkin, H.3
  • 32
    • 33644830890 scopus 로고    scopus 로고
    • Response or not to alfuzosin treatment is predictive of AUR and BPH surgery
    • Suppl, 463
    • Emberton M, Elhilali M, Hartung R, et al. Response or not to alfuzosin treatment is predictive of AUR and BPH surgery. J Urol 2005;173(Suppl), 463, A1708.
    • (2005) J Urol , vol.173
    • Emberton, M.1    Elhilali, M.2    Hartung, R.3
  • 33
    • 0019818985 scopus 로고
    • The natural history of untreated "prostatism
    • Ball AJ, Feneley RCL, Abrahams PH. The natural history of untreated "prostatism". Br J Urol 1981;53:314-16.
    • (1981) Br J Urol , vol.53 , pp. 314-316
    • Ball, A.J.1    Feneley, R.C.L.2    Abrahams, P.H.3
  • 34
    • 0028816195 scopus 로고
    • Comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia
    • Wasson JH, Reda DJ, Bruskewitz RC, et al. Comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. N Engl J Med 1995;332:75-9.
    • (1995) N Engl J Med , vol.332 , pp. 75-79
    • Wasson, J.H.1    Reda, D.J.2    Bruskewitz, R.C.3
  • 35
    • 0023895018 scopus 로고
    • Prostatectomy or conservative management in the treatment of benign prostatic hypertrophy?
    • Kadow C, Feneley RCL, Abrahms PH. Prostatectomy or conservative management in the treatment of benign prostatic hypertrophy? Br J Urol 1988;61:432-4.
    • (1988) Br J Urol , vol.61 , pp. 432-434
    • Kadow, C.1    Feneley, R.C.L.2    Abrahms, P.H.3
  • 36
    • 0017356587 scopus 로고
    • Prostatism and prostatectomy: The value of urine flow rate measurement in the preoperative assessment for operation
    • Abrahms PH. Prostatism and prostatectomy: the value of urine flow rate measurement in the preoperative assessment for operation. J Urol 1977;117:70-1.
    • (1977) J Urol , vol.117 , pp. 70-71
    • Abrahms, P.H.1
  • 37
    • 0024214094 scopus 로고
    • Alpha-adrenergic mechanisms in dynamics of benign prostatic hypertrophy
    • Caine M. Alpha-adrenergic mechanisms in dynamics of benign prostatic hypertrophy. Urology 1988;32:16-20.
    • (1988) Urology , vol.32 , pp. 16-20
    • Caine, M.1
  • 38
    • 0025028657 scopus 로고
    • Medical management of benign prostatic hyperplasia with androgen suppression
    • McConnell JD. Medical management of benign prostatic hyperplasia with androgen suppression. Prostate Suppl 1990;3:49-59.
    • (1990) Prostate Suppl , vol.3 , pp. 49-59
    • McConnell, J.D.1
  • 39
    • 0023227737 scopus 로고
    • The effect of nafarelin acetate, a luteinizing-hormone-releasing hormone agonist on benign prostatic hyperplasia
    • Peters CA, Walsh PC. The effect of nafarelin acetate, a luteinizing-hormone-releasing hormone agonist on benign prostatic hyperplasia. N Engl J Med 1987;317:599-604.
    • (1987) N Engl J Med , vol.317 , pp. 599-604
    • Peters, C.A.1    Walsh, P.C.2
  • 40
    • 0027222669 scopus 로고
    • The alpha-adrenoceptor sub-type mediating the tension of human prostatic smooth muscle
    • Lepor H, Tang R, Shapiro E. The alpha-adrenoceptor sub-type mediating the tension of human prostatic smooth muscle. Prostate 1993;22:301-7.
    • (1993) Prostate , vol.22 , pp. 301-307
    • Lepor, H.1    Tang, R.2    Shapiro, E.3
  • 41
    • 0017076325 scopus 로고
    • The use of alpha-adrenergic blockers in benign prostatic obstruction
    • Caine M, Pfau A, Perlberg S. The use of alpha-adrenergic blockers in benign prostatic obstruction. Br J Urol 1976;48:255-63.
    • (1976) Br J Urol , vol.48 , pp. 255-263
    • Caine, M.1    Pfau, A.2    Perlberg, S.3
  • 42
    • 0030969734 scopus 로고    scopus 로고
    • Prostatic alpha-1 adrenoceptors and uroselectivity
    • Andersson KE, Lepor H, Wyllie MG. Prostatic alpha-1 adrenoceptors and uroselectivity. Prostate 1997;30:202-15.
    • (1997) Prostate , vol.30 , pp. 202-215
    • Andersson, K.E.1    Lepor, H.2    Wyllie, M.G.3
  • 43
    • 0024210187 scopus 로고
    • Laboratory assessment of teraozosin and alpha-1 blockade in prostatic hyperplasia
    • Lepor H, Gup DI, Bauman M, et al. Laboratory assessment of teraozosin and alpha-1 blockade in prostatic hyperplasia. Urology 1988;32(Suppl):21-6.
    • (1988) Urology , vol.32 , Issue.SUPPL. , pp. 21-26
    • Lepor, H.1    Gup, D.I.2    Bauman, M.3
  • 44
    • 0028834573 scopus 로고
    • Long-term efficacy and safety of terazosin in patients with benign prostatic hyperplasia. Terazosin Research Group
    • Lepor H. Long-term efficacy and safety of terazosin in patients with benign prostatic hyperplasia. Terazosin Research Group. Urology 1995;45:406-13.
    • (1995) Urology , vol.45 , pp. 406-413
    • Lepor, H.1
  • 45
    • 0035514595 scopus 로고    scopus 로고
    • Meta-analysis of randomized trials of terazosin in the treatment of benign prostatic hyperplasia
    • Boyle P, Robertson C, Manski R, et al. Meta-analysis of randomized trials of terazosin in the treatment of benign prostatic hyperplasia. Urology 2001;58:717-22.
    • (2001) Urology , vol.58 , pp. 717-722
    • Boyle, P.1    Robertson, C.2    Manski, R.3
  • 46
    • 0029684668 scopus 로고    scopus 로고
    • Benign prostatic hyperplasia: A review of its histogenesis and natural history
    • Oesterling JE. Benign prostatic hyperplasia: a review of its histogenesis and natural history. Prostate Suppl 1996;6:67-73.
    • (1996) Prostate Suppl , vol.6 , pp. 67-73
    • Oesterling, J.E.1
  • 47
    • 0032861498 scopus 로고    scopus 로고
    • Alpha-1 adrenoceptor antagonists, doxazosin and terazosin induce prostate apoptosis without affecting cell proliferation in patients with benign prostatic hyperplasia
    • Chon JK, Borkowski A, Partin AW, et al. Alpha-1 adrenoceptor antagonists, doxazosin and terazosin induce prostate apoptosis without affecting cell proliferation in patients with benign prostatic hyperplasia. J Urol 1999;161:2002-8.
    • (1999) J Urol , vol.161 , pp. 2002-2008
    • Chon, J.K.1    Borkowski, A.2    Partin, A.W.3
  • 48
    • 0032426688 scopus 로고    scopus 로고
    • Induction of prostate apoptosis by doxazosin in benign prostatic hyperplasia
    • Kyprianou N, Litvak J, Borkowski A, et al. Induction of prostate apoptosis by doxazosin in benign prostatic hyperplasia. J Urol 1998;159:1308-12.
    • (1998) J Urol , vol.159 , pp. 1308-1312
    • Kyprianou, N.1    Litvak, J.2    Borkowski, A.3
  • 49
    • 0020406056 scopus 로고
    • A pharmacodynamic and pharmacokinetic assessment of a new alpha-adrenoceptor antagonist, doxazosin (UK-33274) in normotensive subjects
    • Elliot HL, Meredith PA, Sumner DJ, et al. A pharmacodynamic and pharmacokinetic assessment of a new alpha-adrenoceptor antagonist, doxazosin (UK-33274) in normotensive subjects. Br J Clin Pharmacol 1982;13:699-703.
    • (1982) Br J Clin Pharmacol , vol.13 , pp. 699-703
    • Elliot, H.L.1    Meredith, P.A.2    Sumner, D.J.3
  • 50
    • 0028206741 scopus 로고
    • 29 weeks doxazosin treatment in patients with symptomatic benign prostatic hyperplasia
    • Holme JB, Christensen MM, Rasmussen PC, et al. 29 weeks doxazosin treatment in patients with symptomatic benign prostatic hyperplasia. Scand J Urol Nephrol 1994;28:77-82.
    • (1994) Scand J Urol Nephrol , vol.28 , pp. 77-82
    • Holme, J.B.1    Christensen, M.M.2    Rasmussen, P.C.3
  • 51
    • 0030248565 scopus 로고    scopus 로고
    • Safety and efficacy of doxazosin in benign prostatic hyperplasia: A pooled analysis of three, double-blind, placebo-controlled studies
    • Roehrborn CG, Siegel RL. Safety and efficacy of doxazosin in benign prostatic hyperplasia: a pooled analysis of three, double-blind, placebo-controlled studies. Urology 1996;48:406-15.
    • (1996) Urology , vol.48 , pp. 406-415
    • Roehrborn, C.G.1    Siegel, R.L.2
  • 52
    • 0029991306 scopus 로고    scopus 로고
    • Principal results of the Hypertension and Lipid Trial (HALT): A multicenter study of doxazosin in patients with hypertension
    • for the Hypertension and Lipid Trial Study Group
    • Levy D, Walmsley P, Levenstein M, for the Hypertension and Lipid Trial Study Group. Principal results of the Hypertension and Lipid Trial (HALT): a multicenter study of doxazosin in patients with hypertension. Am Heart J 1996;131:966-73.
    • (1996) Am Heart J , vol.131 , pp. 966-973
    • Levy, D.1    Walmsley, P.2    Levenstein, M.3
  • 53
    • 0031950817 scopus 로고    scopus 로고
    • A five-year comparison of doxazosin and atenolol in patients with mild-to-moderate hypertension: Effects on blood pressure, serum lipids, and coronary heart disease risk
    • Daae LNW, Westlie L. A five-year comparison of doxazosin and atenolol in patients with mild-to-moderate hypertension: effects on blood pressure, serum lipids, and coronary heart disease risk. Blood Press 1998;7:39-45.
    • (1998) Blood Press , vol.7 , pp. 39-45
    • Daae, L.N.W.1    Westlie, L.2
  • 54
    • 0036189362 scopus 로고    scopus 로고
    • Combined oral therapy with sildenafil and doxazosin for the treatment of non-organic erectile dysfunction refractory to sildenafil monotherapy
    • DeRose AF, Giglio M, Traverso P, et al. Combined oral therapy with sildenafil and doxazosin for the treatment of non-organic erectile dysfunction refractory to sildenafil monotherapy. Int J Impot Res 2002;14:50-3.
    • (2002) Int J Impot Res , vol.14 , pp. 50-53
    • DeRose, A.F.1    Giglio, M.2    Traverso, P.3
  • 55
    • 14644401842 scopus 로고    scopus 로고
    • The clinical efficacy and tolerability of doxazosin standard and gastrointestinal therapeutic system for benign prostatic hyperplasia
    • Fitzpatrick JM, Desgrandchamps F. The clinical efficacy and tolerability of doxazosin standard and gastrointestinal therapeutic system for benign prostatic hyperplasia. BJU Int 2005;95:575-9.
    • (2005) BJU Int , vol.95 , pp. 575-579
    • Fitzpatrick, J.M.1    Desgrandchamps, F.2
  • 56
    • 0027199688 scopus 로고
    • Alfuzosin, a selective alpha-1 adrenoceptor antagonist in the lower urinary tract
    • Lefevre-Borg F, O'Connor SE, Schoemaker H, et al. Alfuzosin, a selective alpha-1 adrenoceptor antagonist in the lower urinary tract. Br J Pharmacol 1993;109:1282-9.
    • (1993) Br J Pharmacol , vol.109 , pp. 1282-1289
    • Lefevre-Borg, F.1    O'Connor, S.E.2    Schoemaker, H.3
  • 57
    • 33644828388 scopus 로고    scopus 로고
    • Roehrborn CG, for the ALTESS study group. Alfuzosin 10 mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute urinary retention: results of a 2-year placebo-controlled study. BJU Int 2006;97:734-41.
    • Roehrborn CG, for the ALTESS study group. Alfuzosin 10 mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute urinary retention: results of a 2-year placebo-controlled study. BJU Int 2006;97:734-41.
  • 58
    • 2442558026 scopus 로고    scopus 로고
    • Members of ALFAUR study group. Alfuzosin once daily facilitates a return to voiding in patients with acute urinary retention
    • McNeill SA, Hargreave TB, Members of ALFAUR study group. Alfuzosin once daily facilitates a return to voiding in patients with acute urinary retention. J Urol 2004;171:2316-20.
    • (2004) J Urol , vol.171 , pp. 2316-2320
    • McNeill, S.A.1    Hargreave, T.B.2
  • 59
    • 12844253013 scopus 로고    scopus 로고
    • ALFAUR study group. Alfuzosin 10 mg once daily in the management of acute urinary retention: Results of a double-blind placebo-controlled study
    • McNeill SA, Hargreave TB, Roehrborn CG, ALFAUR study group. Alfuzosin 10 mg once daily in the management of acute urinary retention: results of a double-blind placebo-controlled study. Urology 2005;65:83-9.
    • (2005) Urology , vol.65 , pp. 83-89
    • McNeill, S.A.1    Hargreave, T.B.2    Roehrborn, C.G.3
  • 60
    • 0033998198 scopus 로고    scopus 로고
    • Efficacy and safety of a new prolonged release formulation of alfuzosin 10 mg once daily versus alfuzosin 2.5 mg thrice daily and placebo in patients with symptomatic benign prostatic hyperplasia. ALFORTI study group
    • van Kerrebroeck P, Jardin A, Laval KU, et al. Efficacy and safety of a new prolonged release formulation of alfuzosin 10 mg once daily versus alfuzosin 2.5 mg thrice daily and placebo in patients with symptomatic benign prostatic hyperplasia. ALFORTI study group. Eur Urol 2000;37:306-13.
    • (2000) Eur Urol , vol.37 , pp. 306-313
    • van Kerrebroeck, P.1    Jardin, A.2    Laval, K.U.3
  • 61
    • 0035667615 scopus 로고    scopus 로고
    • Efficacy and safety of once daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: A randomized placebo-controlled trial. ALFUS Study Group
    • Roehrborn GC. Efficacy and safety of once daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a randomized placebo-controlled trial. ALFUS Study Group. Urology 2001;58:953-9.
    • (2001) Urology , vol.58 , pp. 953-959
    • Roehrborn, G.C.1
  • 62
    • 0029843393 scopus 로고    scopus 로고
    • Tamsulosin. A review of its pharmacological properties and therapeutic potential in the management of symptomatic benign prostatic hyperplasia
    • Wilde MI, McTavish D. Tamsulosin. A review of its pharmacological properties and therapeutic potential in the management of symptomatic benign prostatic hyperplasia. Drugs 1996;52:883-98.
    • (1996) Drugs , vol.52 , pp. 883-898
    • Wilde, M.I.1    McTavish, D.2
  • 63
    • 0030752642 scopus 로고    scopus 로고
    • Pharmacology of tamsulosin: Saturation-binding isotherms and competition analysis using cloned alpha-1 adrenergic subtypes
    • Richardson CD, Donatussi CF, Page SO, et al. Pharmacology of tamsulosin: saturation-binding isotherms and competition analysis using cloned alpha-1 adrenergic subtypes. Prostate 1997;33:55-9.
    • (1997) Prostate , vol.33 , pp. 55-59
    • Richardson, C.D.1    Donatussi, C.F.2    Page, S.O.3
  • 64
    • 0029098058 scopus 로고
    • Tamsulosin, a selective alpha-1a adrenoceptor antagonist: A randomized controlled trial in patients with benign prostatic "obstruction" (symptomatic BPH)
    • Abrams P, Schulman CC, Vaage S, et al. Tamsulosin, a selective alpha-1a adrenoceptor antagonist: a randomized controlled trial in patients with benign prostatic "obstruction" (symptomatic BPH). Br J Urol 1995;76:325-36.
    • (1995) Br J Urol , vol.76 , pp. 325-336
    • Abrams, P.1    Schulman, C.C.2    Vaage, S.3
  • 65
    • 0030065315 scopus 로고    scopus 로고
    • Tamsulosin, the first prostate-selective alpha-1a adrenoceptor antagonist. A meta-analysis of two randomized, placebo-controlled, multicentre studies in patients with benign prostatic obstruction (symptomatic BPH)
    • Chapple CR, Wyndaele JJ, Nordling J, et al. Tamsulosin, the first prostate-selective alpha-1a adrenoceptor antagonist. A meta-analysis of two randomized, placebo-controlled, multicentre studies in patients with benign prostatic obstruction (symptomatic BPH). Eur Urol 1996;29:155-67.
    • (1996) Eur Urol , vol.29 , pp. 155-167
    • Chapple, C.R.1    Wyndaele, J.J.2    Nordling, J.3
  • 66
    • 0031403134 scopus 로고    scopus 로고
    • A dose-ranging study of the efficacy and safety of tamsulosin, the first prostate-selective alpha-1a adrenoceptor antagonist, in patients with benign prostatic obstruction (symptomatic benign prostatic hyperplasia)
    • Abrams P, Speakman M, Stott M, et al. A dose-ranging study of the efficacy and safety of tamsulosin, the first prostate-selective alpha-1a adrenoceptor antagonist, in patients with benign prostatic obstruction (symptomatic benign prostatic hyperplasia). Br J Urol 1997;80:587-96.
    • (1997) Br J Urol , vol.80 , pp. 587-596
    • Abrams, P.1    Speakman, M.2    Stott, M.3
  • 67
    • 0007563480 scopus 로고    scopus 로고
    • European pressure-flow investigation of tamsulosin in men with lower urinary tract symptoms (LUTS) suggestive of benign prostatic obstruction (BPO) - ESPIRIT study
    • Abrams P, Tammela TL, Hellstrom P, et al. European pressure-flow investigation of tamsulosin in men with lower urinary tract symptoms (LUTS) suggestive of benign prostatic obstruction (BPO) - ESPIRIT study. J Urol 1998;159(Suppl 5):256.
    • (1998) J Urol , vol.159 , Issue.SUPPL. 5 , pp. 256
    • Abrams, P.1    Tammela, T.L.2    Hellstrom, P.3
  • 69
    • 0038286511 scopus 로고    scopus 로고
    • Combination treatment with an alpha-blocker plus an anticholinergic for bladder outlet obstruction: A prospective, randomized, controlled study
    • Athanasopoulos A, Gyftopoulos K, Giannitsas K, et al. Combination treatment with an alpha-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized, controlled study. J Urol 2003;169:2253-6.
    • (2003) J Urol , vol.169 , pp. 2253-2256
    • Athanasopoulos, A.1    Gyftopoulos, K.2    Giannitsas, K.3
  • 70
    • 28244436182 scopus 로고    scopus 로고
    • Efficacy of the combination of an alpha 1-blocker with an anticholinergic agent in the treatment of lower urinary tract symptoms associated with bladder outlet obstruction
    • Athanasopoulos A, Perimenis P. Efficacy of the combination of an alpha 1-blocker with an anticholinergic agent in the treatment of lower urinary tract symptoms associated with bladder outlet obstruction. Expert Opin Pharmacother 2005;6:2429-33.
    • (2005) Expert Opin Pharmacother , vol.6 , pp. 2429-2433
    • Athanasopoulos, A.1    Perimenis, P.2
  • 71
    • 0033625134 scopus 로고    scopus 로고
    • Dihydrotestosterone and the concept of 5 alpha-reductase inhibitors in human benign prostatic hyperplasia
    • Bartsch G, Rittmaster RS, Klocker H. Dihydrotestosterone and the concept of 5 alpha-reductase inhibitors in human benign prostatic hyperplasia. Eur Urol 2000;37:367-80.
    • (2000) Eur Urol , vol.37 , pp. 367-380
    • Bartsch, G.1    Rittmaster, R.S.2    Klocker, H.3
  • 72
    • 0016304673 scopus 로고
    • Familial incomplete male pseudohermaphroditism, type 2: Decreased dihydrotestosterone formation in pseudovaginal perineo-scrotal hypospadias
    • Walsh PC, Madden JD, Harrod MJ, et al. Familial incomplete male pseudohermaphroditism, type 2: decreased dihydrotestosterone formation in pseudovaginal perineo-scrotal hypospadias. N Engl J Med 1974;291:944-9.
    • (1974) N Engl J Med , vol.291 , pp. 944-949
    • Walsh, P.C.1    Madden, J.D.2    Harrod, M.J.3
  • 73
    • 0016359646 scopus 로고
    • Steroid 5-alpha reductase deficiency in man: An inherited form of male pseudohermaphroditism
    • Imperato-McGinley J, Guerrero L, Gautier T, et al. Steroid 5-alpha reductase deficiency in man: an inherited form of male pseudohermaphroditism. Science 1974;186:1213-15.
    • (1974) Science , vol.186 , pp. 1213-1215
    • Imperato-McGinley, J.1    Guerrero, L.2    Gautier, T.3
  • 74
    • 0022455392 scopus 로고
    • Prostatic effects induced in dogs by chronic or acute oral administration of 5-alpha reductase inhibitors
    • Brooks JR, Berman C, Garnes D, et al. Prostatic effects induced in dogs by chronic or acute oral administration of 5-alpha reductase inhibitors. Prostate 1986;9:65-75.
    • (1986) Prostate , vol.9 , pp. 65-75
    • Brooks, J.R.1    Berman, C.2    Garnes, D.3
  • 75
    • 0024335880 scopus 로고
    • Effect of MK-906, a specific 5-alpha reductase inhibitor, on serum androgens and androgen conjugates in normal men
    • Rittmaster RS, Stoner E, Thompson DL, et al. Effect of MK-906, a specific 5-alpha reductase inhibitor, on serum androgens and androgen conjugates in normal men. J Androl 1989;10:259-62.
    • (1989) J Androl , vol.10 , pp. 259-262
    • Rittmaster, R.S.1    Stoner, E.2    Thompson, D.L.3
  • 76
    • 0031744756 scopus 로고    scopus 로고
    • Long-term effects of finasteride in patients with benign prostatic hyperplasia: A double-blind, placebo-controlled, multicenter study. PROWESS Study Group
    • Marberger MJ. Long-term effects of finasteride in patients with benign prostatic hyperplasia: a double-blind, placebo-controlled, multicenter study. PROWESS Study Group. Urology 1998;51:677-86.
    • (1998) Urology , vol.51 , pp. 677-686
    • Marberger, M.J.1
  • 77
    • 9444268678 scopus 로고    scopus 로고
    • The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group
    • Lepor H, Williford WO, Barry MJ, et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. N Engl J Med 1996;335:533-9.
    • (1996) N Engl J Med , vol.335 , pp. 533-539
    • Lepor, H.1    Williford, W.O.2    Barry, M.J.3
  • 78
    • 0031718686 scopus 로고    scopus 로고
    • Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia. European ALFIN Study Group
    • Debruyne FM, Jardin A, Colloi D, et al. Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia. European ALFIN Study Group. Eur Urol 1998;34:169-75.
    • (1998) Eur Urol , vol.34 , pp. 169-175
    • Debruyne, F.M.1    Jardin, A.2    Colloi, D.3
  • 79
    • 0037253614 scopus 로고    scopus 로고
    • Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: The Prospective European Doxazosin and Combination Therapy (PREDICT) trial
    • Kirby RS, Roehrborn C, Boyle P, et al. Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial. Urology 2003;61:119-26.
    • (2003) Urology , vol.61 , pp. 119-126
    • Kirby, R.S.1    Roehrborn, C.2    Boyle, P.3
  • 80
    • 0030249241 scopus 로고    scopus 로고
    • Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: Meta-analysis of randomized clinical trials
    • Boyde P, Gould AI, Roehrborn G. Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials. Urology 1996;48:398-405.
    • (1996) Urology , vol.48 , pp. 398-405
    • Boyde, P.1    Gould, A.I.2    Roehrborn, G.3
  • 81
    • 0033978614 scopus 로고    scopus 로고
    • A prospective study of the natural history of hematuria associated with benign prostatic hyperplasia and the effect of finasteride
    • Foley SJ, Soloman LZ, Wedderburn AW, et al. A prospective study of the natural history of hematuria associated with benign prostatic hyperplasia and the effect of finasteride. J Urol 2000;163:496-8.
    • (2000) J Urol , vol.163 , pp. 496-498
    • Foley, S.J.1    Soloman, L.Z.2    Wedderburn, A.W.3
  • 82
    • 0036093270 scopus 로고    scopus 로고
    • Clinical predictors in the use of finasteride for control of gross hematuria due to benign prostatic hyperplasia
    • Kearney MC, Bingham JB, Bergland R, et al. Clinical predictors in the use of finasteride for control of gross hematuria due to benign prostatic hyperplasia. J Urol 2002;167:2489-91.
    • (2002) J Urol , vol.167 , pp. 2489-2491
    • Kearney, M.C.1    Bingham, J.B.2    Bergland, R.3
  • 83
    • 0036191105 scopus 로고    scopus 로고
    • Effects of finasteride and cyproterone acetate on hematuria associated with benign prostatic hyperplasia: A prospective, randomized, controlled study
    • Perimenis P, Gyftopoulos K, Markou S, et al. Effects of finasteride and cyproterone acetate on hematuria associated with benign prostatic hyperplasia: a prospective, randomized, controlled study. Urology 2002;59:373-7.
    • (2002) Urology , vol.59 , pp. 373-377
    • Perimenis, P.1    Gyftopoulos, K.2    Markou, S.3
  • 84
    • 0037213171 scopus 로고    scopus 로고
    • The effect of finasteride on the expression of vascular endothelial growth factor and microvessel density: A possible mechanism for decreased prostatic bleeding in treated patients
    • Pareek G, Shevchuk M, Armenakas NA, et al. The effect of finasteride on the expression of vascular endothelial growth factor and microvessel density: a possible mechanism for decreased prostatic bleeding in treated patients. J Urol 2003;169:20-3.
    • (2003) J Urol , vol.169 , pp. 20-23
    • Pareek, G.1    Shevchuk, M.2    Armenakas, N.A.3
  • 85
    • 0035667075 scopus 로고    scopus 로고
    • Blood loss during transurethral resection of the prostate after 3 months of treatment with finasteride
    • Sandfelt L, Bailey DM, Hahn RG. Blood loss during transurethral resection of the prostate after 3 months of treatment with finasteride. Urology 2001;58:972-6.
    • (2001) Urology , vol.58 , pp. 972-976
    • Sandfelt, L.1    Bailey, D.M.2    Hahn, R.G.3
  • 86
    • 0036432805 scopus 로고    scopus 로고
    • Changes in molecular forms of prostate-specific antigen during treatment with finasteride
    • Espana F, Martinez M, Royo M, et al. Changes in molecular forms of prostate-specific antigen during treatment with finasteride. BJU Int 2002;90:672-7.
    • (2002) BJU Int , vol.90 , pp. 672-677
    • Espana, F.1    Martinez, M.2    Royo, M.3
  • 87
    • 0037812658 scopus 로고    scopus 로고
    • The influence of finasteride on the development of prostate cancer
    • Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003;349:215-24.
    • (2003) N Engl J Med , vol.349 , pp. 215-224
    • Thompson, I.M.1    Goodman, P.J.2    Tangen, C.M.3
  • 88
    • 27744492261 scopus 로고    scopus 로고
    • The effects of 5alpha-reductase inhibitors on the natural history, detection and grading of prostate cancer: Current state of knowledge
    • Andriole G, Bostwick D, Civantos F, et al. The effects of 5alpha-reductase inhibitors on the natural history, detection and grading of prostate cancer: current state of knowledge. J Urol 2005;174:2098- 104.
    • (2005) J Urol , vol.174 , pp. 2098-2104
    • Andriole, G.1    Bostwick, D.2    Civantos, F.3
  • 89
    • 0028173882 scopus 로고
    • Steroid 5-alpha reductase: Two genes/two enzymes
    • Russell DW, Wilson JD. Steroid 5-alpha reductase: two genes/two enzymes. Annu Rev Biochem 1994;63:25-61.
    • (1994) Annu Rev Biochem , vol.63 , pp. 25-61
    • Russell, D.W.1    Wilson, J.D.2
  • 90
    • 0027234897 scopus 로고
    • Tissue distribution and ontogeny of steroid 5-alpha reductase isozyme expression
    • Thipen AE, Silver RI, Guileyardo JM, et al. Tissue distribution and ontogeny of steroid 5-alpha reductase isozyme expression. J Clin Invest 1993;92:903-10.
    • (1993) J Clin Invest , vol.92 , pp. 903-910
    • Thipen, A.E.1    Silver, R.I.2    Guileyardo, J.M.3
  • 91
    • 0025275489 scopus 로고
    • Effects of finasteride (MK-906), a 5-alpha reductase inhibitor, on circulating androgens in male volunteers
    • Gormley GL, Stoner E, Rittmaster RS, et al. Effects of finasteride (MK-906), a 5-alpha reductase inhibitor, on circulating androgens in male volunteers. J Clin Endocrinol Metab 1990;70:1136-41.
    • (1990) J Clin Endocrinol Metab , vol.70 , pp. 1136-1141
    • Gormley, G.L.1    Stoner, E.2    Rittmaster, R.S.3
  • 92
    • 0026000965 scopus 로고
    • Hormonal effects, tolerability, and preliminary kinetics in men of MK-906, a 5-alpha reductase inhibitor
    • De Schepper PJ, Imperato-McGinley J, Van Hecken A, et al. Hormonal effects, tolerability, and preliminary kinetics in men of MK-906, a 5-alpha reductase inhibitor. Steroids 1991;56:469-71.
    • (1991) Steroids , vol.56 , pp. 469-471
    • De Schepper, P.J.1    Imperato-McGinley, J.2    Van Hecken, A.3
  • 93
    • 0028807269 scopus 로고
    • Mechanism of time-dependent inhibition of 5 alpha-reductases by 4-azasteroids: Towards perfection of rates of time-dependent inhibition by using ligand-binding energies
    • Tian G, Mook RA, Moss ML, et al. Mechanism of time-dependent inhibition of 5 alpha-reductases by 4-azasteroids: towards perfection of rates of time-dependent inhibition by using ligand-binding energies. Biochemistry 1995;34:13453-9.
    • (1995) Biochemistry , vol.34 , pp. 13453-13459
    • Tian, G.1    Mook, R.A.2    Moss, M.L.3
  • 94
    • 0030886845 scopus 로고    scopus 로고
    • Unique preclinical characteristics of GG745, a potent dual inhibitor of 5AR
    • Bramson HN, Hermann D, Batchelor KW, et al. Unique preclinical characteristics of GG745, a potent dual inhibitor of 5AR. J Pharmacol Exp Ther 1997;282:1496-502.
    • (1997) J Pharmacol Exp Ther , vol.282 , pp. 1496-1502
    • Bramson, H.N.1    Hermann, D.2    Batchelor, K.W.3
  • 95
    • 0000006973 scopus 로고    scopus 로고
    • Effective suppression of dihydrotestosterone (DHT) in men by GIl98745: A novel dual 5 alpha-reductase inhibitor. Abstract S1737
    • Clark RV, Hermann DJ, Gabriel H, et al. Effective suppression of dihydrotestosterone (DHT) in men by GIl98745: a novel dual 5 alpha-reductase inhibitor. Abstract S1737. J Urol 1999;164(Suppl 4):268.
    • (1999) J Urol , vol.164 , Issue.SUPPL. 4 , pp. 268
    • Clark, R.V.1    Hermann, D.J.2    Gabriel, H.3
  • 96
    • 0036754256 scopus 로고    scopus 로고
    • Efficacy and safety of a dual inhibitor of 5 alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia
    • Roehrborn CG, Boyle P, Nickel JC, et al. Efficacy and safety of a dual inhibitor of 5 alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002;60:434-41.
    • (2002) Urology , vol.60 , pp. 434-441
    • Roehrborn, C.G.1    Boyle, P.2    Nickel, J.C.3
  • 97
    • 24044473719 scopus 로고    scopus 로고
    • Long-term sustained improvement in symptoms of benign prostatic hyperplasia with dual 5a-reductase inhibitor dutasteride: Results of 4-year studies
    • Roehrborn CG, Lukkarinen O, Mark S, et al. Long-term sustained improvement in symptoms of benign prostatic hyperplasia with dual 5a-reductase inhibitor dutasteride: results of 4-year studies. BJU Int 2005;96:572-7.
    • (2005) BJU Int , vol.96 , pp. 572-577
    • Roehrborn, C.G.1    Lukkarinen, O.2    Mark, S.3
  • 98
    • 17444399653 scopus 로고    scopus 로고
    • An evidence-based approach to understanding class effect in the management of prostatic diseases
    • Evans CP, Fleshner N, Fitzpatrick JM, et al. An evidence-based approach to understanding class effect in the management of prostatic diseases. BJU Int 2005;95:743-9.
    • (2005) BJU Int , vol.95 , pp. 743-749
    • Evans, C.P.1    Fleshner, N.2    Fitzpatrick, J.M.3
  • 99
    • 0033919056 scopus 로고    scopus 로고
    • A scientific basis for the therapeutic effects of Pygeum africanum and Serenoa repens
    • Levin RM, Das AK. A scientific basis for the therapeutic effects of Pygeum africanum and Serenoa repens. Urol Res 2000;28:201-9.
    • (2000) Urol Res , vol.28 , pp. 201-209
    • Levin, R.M.1    Das, A.K.2
  • 100
    • 0029007017 scopus 로고
    • Phytotherapeutic agents in the management of symptomatic benign prostatic hyperplasia
    • Fitzpatrick JM, Lynch TH. Phytotherapeutic agents in the management of symptomatic benign prostatic hyperplasia. Urol Clin North Am 1995;22:407-12.
    • (1995) Urol Clin North Am , vol.22 , pp. 407-412
    • Fitzpatrick, J.M.1    Lynch, T.H.2
  • 101
    • 0000435965 scopus 로고    scopus 로고
    • Phytotherapeutic agents
    • Kirby R, McConnell JD, Fitzpatrick JM, et al, eds, Oxford: Isis Medical Media
    • Fitzpatrick JM, Lynch TH. Phytotherapeutic agents. In: Kirby R, McConnell JD, Fitzpatrick JM, et al, eds. Textbook of benign prostatic hyperplasia. Oxford: Isis Medical Media, 1996:331-7.
    • (1996) Textbook of benign prostatic hyperplasia , pp. 331-337
    • Fitzpatrick, J.M.1    Lynch, T.H.2
  • 102
    • 0036139887 scopus 로고    scopus 로고
    • Phytotherapy in the treatment of benign prostatic hyperplasia
    • Lowe FC, Fagelman E. Phytotherapy in the treatment of benign prostatic hyperplasia. Curr Opin Urol 2002;12:15-18.
    • (2002) Curr Opin Urol , vol.12 , pp. 15-18
    • Lowe, F.C.1    Fagelman, E.2
  • 103
    • 0026469615 scopus 로고
    • Evidence that Serenoa repens extract displays an antioestrogenic activity in prostatic tissue of benign prostatic hypertrophy patients
    • DiSilverio F, D'Eramo G, Lubrano C, et al. Evidence that Serenoa repens extract displays an antioestrogenic activity in prostatic tissue of benign prostatic hypertrophy patients. Eur Urol 1992;21:309-14.
    • (1992) Eur Urol , vol.21 , pp. 309-314
    • DiSilverio, F.1    D'Eramo, G.2    Lubrano, C.3
  • 104
    • 0028050246 scopus 로고
    • Comparison of Finasteride (Proscar) and Serenoa repens (Permixon) in the inhibition of 5-alpha reductase in healthy male volunteers
    • Stauch G, Perles P, Vergult G, et al. Comparison of Finasteride (Proscar) and Serenoa repens (Permixon) in the inhibition of 5-alpha reductase in healthy male volunteers. Eur Urol 1994;26:247-52.
    • (1994) Eur Urol , vol.26 , pp. 247-252
    • Stauch, G.1    Perles, P.2    Vergult, G.3
  • 105
    • 0009676274 scopus 로고    scopus 로고
    • Effect of Permixon on apoptosis and proliferation in the prostate of patients with BPH
    • Vacherot F, Azzouz M, Gil-Diez-de-Medina S, et al. Effect of Permixon on apoptosis and proliferation in the prostate of patients with BPH. J Urol 1999;161:362.
    • (1999) J Urol , vol.161 , pp. 362
    • Vacherot, F.1    Azzouz, M.2    Gil-Diez-de-Medina, S.3
  • 106
    • 0029859371 scopus 로고    scopus 로고
    • Serenoa repens (Permixon): A review of its pharmacology and therapeutic efficacy in benign prostatic hyperplasia
    • Plosker GL, Brogden RN. Serenoa repens (Permixon): a review of its pharmacology and therapeutic efficacy in benign prostatic hyperplasia. Drugs Aging 1996;9:379-95.
    • (1996) Drugs Aging , vol.9 , pp. 379-395
    • Plosker, G.L.1    Brogden, R.N.2
  • 107
    • 0029097408 scopus 로고
    • Pygeum africanum extract for the treatment of patients with benign prostatic hyperplosia: Review of 25 years of published experience
    • Andro MC, Riffaud JP. Pygeum africanum extract for the treatment of patients with benign prostatic hyperplosia: review of 25 years of published experience. Curr Therap Res 1995;56:796-817.
    • (1995) Curr Therap Res , vol.56 , pp. 796-817
    • Andro, M.C.1    Riffaud, J.P.2
  • 110
    • 1842376945 scopus 로고    scopus 로고
    • Discrepancies between meta-analyses and subsequent large randomized controlled trials
    • DeLorier J, Gregoire G, Benhaddad A, et al. Discrepancies between meta-analyses and subsequent large randomized controlled trials. N Engl J Med 1997;337:536-42.
    • (1997) N Engl J Med , vol.337 , pp. 536-542
    • DeLorier, J.1    Gregoire, G.2    Benhaddad, A.3
  • 111
    • 0347318854 scopus 로고    scopus 로고
    • Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostatic hyperplasia: A randomized international study of 1089 patients
    • Carraro JC, Raynaud JP, Koch G, et al. Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostatic hyperplasia: a randomized international study of 1089 patients. Prostate 1996;29:231-40.
    • (1996) Prostate , vol.29 , pp. 231-240
    • Carraro, J.C.1    Raynaud, J.P.2    Koch, G.3
  • 112
    • 0036587080 scopus 로고    scopus 로고
    • Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (tamsulosin) in the treatment of benign prostatic hyperplasia: A 1-year randomized international study
    • Debruyne F, Koch G, Boyle P, et al. Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study. Eur Urol 2002;41:497-507.
    • (2002) Eur Urol , vol.41 , pp. 497-507
    • Debruyne, F.1    Koch, G.2    Boyle, P.3
  • 113
    • 0029206194 scopus 로고
    • Comparative effects of alfuzosin versus Serenoa repens in the treatment of symptomatic benign prostatic hyperplasia
    • Grasso M, Montesano A, Buonaguidi A, et al. Comparative effects of alfuzosin versus Serenoa repens in the treatment of symptomatic benign prostatic hyperplasia. Arch Esp Urol 1995;48:97-103.
    • (1995) Arch Esp Urol , vol.48 , pp. 97-103
    • Grasso, M.1    Montesano, A.2    Buonaguidi, A.3
  • 114
    • 33847360329 scopus 로고    scopus 로고
    • th international consultation of BPH. Recommendations of the international scientific committee: the evaluation and treatment of lower urinary tract syndromes (LUTS) suggestive of benign prostatic obstruction. In: Denis L, Griffiths K, Khoury S, et al, eds. Proceedings of the fourth international consultation of benign prostatic hyperplasia (BPH). Plymouth: Plymouth Distributors, 1998:669-984.
    • th international consultation of BPH. Recommendations of the international scientific committee: the evaluation and treatment of lower urinary tract syndromes (LUTS) suggestive of benign prostatic obstruction. In: Denis L, Griffiths K, Khoury S, et al, eds. Proceedings of the fourth international consultation of benign prostatic hyperplasia (BPH). Plymouth: Plymouth Distributors, 1998:669-984.


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.